Jim Simons
BDRX

Jim Simons’s Biodexa Pharmaceuticals BDRX Stock Holding History

Jim Simons’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9
Closed -$31K – 3708
2023
Q4 		$31K Buy
+9
New +$38.2K ﹤0.01% 3525
2023
Q2 		– Sell
-1
Closed -$21K – 3912
2023
Q1 		$21K Buy
+1
New +$225K ﹤0.01% 3811
2022
Q4 		– Hold
0
– – – 3864
2022
Q3 		– Hold
0
– – – 3679
2022
Q2 		– Hold
0
– – – 3824
2022
Q1 		– Hold
0
– – – 3680
2021
Q4 		– Hold
0
– – – 3483
2021
Q3 		– Hold
0
– – – 2997
2021
Q2 		– Hold
0
– – – 3010
2021
Q1 		– Hold
0
– – – 2738
2020
Q4 		– Hold
0
– – – 2992
2020
Q3 		– Hold
0
– – – 3026
2020
Q2 		– Hold
0
– – – 3313
2020
Q1 		– Hold
0
– – – 3361
2019
Q4 		– Hold
0
– – – 3317
2019
Q2 		– Hold
0
– -$150K – 3541
2019
Q1 		– Hold
0
– – – 3248
2016
Q2 		– Hold
0
– -$85K – 3326
2016
Q1 		– Hold
0
– – – 3232
2015
Q4 		– Hold
0
– – – 2994

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's BDRX Position: Q1 2024 in Review

Jim Simons sold out of Biodexa Pharmaceuticals (BDRX) in Q1 2024, closing a stake of 9 shares — an estimated $31K sold.

Jim Simons first reported a position in BDRX in Q1 2023 and held it in 2 quarters. The position peaked at $31K in Q4 2023. 3 funds tracked by Wall St. Rank hold BDRX as of Q1 2024.

  • Jim Simons reported no remaining Biodexa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Jim Simons sold 9 Biodexa Pharmaceuticals shares in Q1 2024, an estimated $31K.
  • Jim Simons first reported a position in Biodexa Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Jim Simons's Biodexa Pharmaceuticals position peaked at $31K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.